Barclays analyst Matt Miksic raised the firm’s price target on Globus Medical (GMED) to $100 from $93 and keeps an Overweight rating on the shares. The company is on track to return to mid-to-high single-digit sales growth and mid-30’s EBITDA margins, the analyst tells investors in a research note. The firm views Globus Medical’s earnings beat as “impressive” on strong sales and accelerating cost synergies.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMED:
- Globus Medical price target raised to $85 from $70 at Canaccord
- Globus Medical price target raised to $100 from $80 at Piper Sandler
- Globus Medical price target raised to $87 from $78 at BTIG
- Globus Medical price target raised to $80 from $55 at BofA
- Globus Medical price target raised to $88 from $78 at Wells Fargo
Questions or Comments about the article? Write to editor@tipranks.com